Form 4: Vertex Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer of Vertex Pharmaceuticals, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On February 10, 2025, Edward Morrow Atkinson III, EVP, Chief Technical Operations Officer of Vertex Pharmaceuticals, had 876 shares of common stock disposed of at a price of $467.98.
• On February 11, 2025, Atkinson sold 1,747 shares of Vertex Pharmaceuticals common stock at a price of $459.83.
• Following these transactions, Atkinson directly owns 23,225 shares of Vertex Pharmaceuticals common stock.
• The sales were executed under a company-approved trading plan pursuant to Rule 10b5-1, which was entered into on February 22, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They can be driven by a variety of factors, including personal financial planning and diversification. The use of 10b5-1 trading plans allows insiders to sell shares at predetermined times and prices, avoiding accusations of insider trading.

Stakeholder Impact

• The stock sale by a high-ranking executive could potentially create uncertainty among shareholders, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates